Stephen Cavanah, MD
Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1427045723
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,956 of the $3,371 with a category attached, or 87.7%. It is spread thinly across 25 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,714 and has fallen 92.7% since, to $125 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in KY, where the typical reported total is $3,450.
Across 158 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$587
- Novo Nordisk$492
- Tandem Diabetes Care, Inc.$438
- Insulet Corporation$312
- Dexcom, Inc.$202
- Sanofi-aventis U.S. LLC$181
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$40012%
- Food & beverage$2,95688%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 15 | $587 |
| Novo Nordisk | 45 | $492 |
| Tandem Diabetes Care, Inc. | 4 | $438 |
| Insulet Corporation | 7 | $312 |
| Dexcom, Inc. | 8 | $202 |
| Sanofi-aventis U.S. LLC | 5 | $181 |
| Amarin Pharma, Inc. | 12 | $169 |
| Boehringer Ingelheim | 13 | $142 |
| Lilly USA, LLC | 9 | $140 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Abbott | 5 | $97 |
| Johnson & Johnson | 5 | $72 |
| AbbVie | 3 | $57 |
| Shire North American Group Inc | 4 | $54 |
| Corcept Therapeutics | 3 | $45 |
| Antares Pharma, Inc. | 3 | $41 |
| Lifescan, Inc. | 3 | $38 |
| Merck | 3 | $35 |
| Amgen(2 entities) | 2 | $32 |
| IBSA Pharma Inc. | 2 | $29 |
| AstraZeneca | 2 | $28 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
| Companion Medical, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$400
- MINIMED 780G$247
- Omnipod$247
- Yorvipath$125
- Minimed 670G System$109
- DEXCOM G7 GSS (161)$106
How this compares
$3,371 in reported general payments places this provider in the 45th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $268,110 |
| TrulicityDulaglutide | 98 | $159,864 |
| Tresiba Flextouch U-200Insulin Degludec | 73 | $131,759 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $115,728 |
| Humalog Kwikpen U-200Insulin Lispro | 32 | $84,620 |
| JardianceEmpagliflozin | 59 | $73,893 |
| MounjaroTirzepatide | 42 | $58,038 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $31,548 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $26,271 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $22,730 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $18,734 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $18,217 |
| JanuviaSitagliptin Phosphate | 19 | $17,619 |
| Novolog FlexpenInsulin Aspart | 38 | $17,278 |
| VascepaIcosapent Ethyl | 30 | $17,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $492 | $268,110134 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $140 | $219,444156 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $142 | $87,48470 claims |
| MerckJanumet, Januvia, Janumet Xr | $35 | $41,42344 claims |
| AbbVieSynthroid | $57 | $2,33359 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Louisville
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Mehdi PoorkayLouisville$81K
- Angelino YsonLouisville$15K
- Mary SelfLouisville$14K
- Omolara FakunleLouisville$13K
- Kaitlyn TuckerLouisville$9K
- Manikya KuritiLouisville$7K
- Carol ToumaLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.